| Not Yet Recruiting | Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC NCT07523789 | The First Affiliated Hospital with Nanjing Medical University | — |
| Not Yet Recruiting | A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in NCT07441512 | Hu Hai | Phase 2 |
| Recruiting | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871 | Radiopharm Theranostics, Ltd | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Can NCT07321015 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer NCT07457359 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Not Yet Recruiting | TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab ( NCT07271992 | First Hospital of China Medical University | Phase 2 |
| Not Yet Recruiting | Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC NCT07244874 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Not Yet Recruiting | Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemother NCT07256964 | Henan Cancer Hospital | Phase 2 |
| Recruiting | MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC NCT07327021 | Tel-Aviv Sourasky Medical Center | Phase 2 |
| Recruiting | A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC NCT07178171 | Xijing Hospital | Phase 1 |
| Recruiting | Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Brea NCT07211178 | Tempus AI | — |
| Recruiting | Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07) NCT07351487 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Not Yet Recruiting | SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers NCT07080619 | Tianjin ConjuStar Biologics Co., Ltd. | Phase 2 |
| Not Yet Recruiting | A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemothera NCT07101614 | Shengjing Hospital | Phase 2 |
| Not Yet Recruiting | ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and R NCT07015853 | Stephen Shiao | Phase 2 |
| Recruiting | Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple NCT07017673 | Cedars-Sinai Medical Center | Phase 2 |
| Not Yet Recruiting | SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer NCT06819319 | Henan Cancer Hospital | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer NCT06977542 | Fudan University | Phase 2 |
| Recruiting | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies NCT07327489 | Elephas | — |
| Recruiting | NearWave Optical Molecular Monitoring NCT06744465 | Indiana University | N/A |
| Recruiting | Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast C NCT06637306 | Rima Patel | EARLY_Phase 1 |
| Recruiting | Trop-2 Targeted PET Probes in Advanced TNBC NCT07046455 | Peking University Cancer Hospital & Institute | N/A |
| Not Yet Recruiting | Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Canc NCT06798506 | Fudan University | — |
| Recruiting | First in Human Study of TUB-030 in Patients With Advanced Solid Tumors NCT06657222 | Tubulis GmbH | Phase 1 / Phase 2 |
| Recruiting | SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC NCT06627712 | West China Hospital | Phase 3 |
| Recruiting | Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SA NCT06358573 | Swiss Cancer Institute | Phase 2 |
| Recruiting | QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC NCT06786026 | Fudan University | Phase 2 |
| Recruiting | Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) NCT06682195 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Recruiting | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer NCT06568692 | Processa Pharmaceuticals | Phase 2 |
| Recruiting | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study NCT06534762 | Zhejiang Provincial People's Hospital | Phase 2 |
| Recruiting | LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Br NCT06387628 | Fudan University | Phase 2 |
| Recruiting | 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962 | Radiopharm Theranostics, Ltd | EARLY_Phase 1 |
| Recruiting | Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer NCT05914961 | University Hospital Tuebingen | — |
| Not Yet Recruiting | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer NCT06404736 | Fudan University | Phase 2 |
| Recruiting | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors NCT06257264 | BeiGene | Phase 1 |
| Recruiting | Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer NCT06220214 | Alison Stopeck | EARLY_Phase 1 |
| Withdrawn | Chemo-free BRCA-targeted Neoadjuvant Strategy NCT05209529 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Not Yet Recruiting | Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours NCT05698238 | Mabpro, a.s. | Phase 1 |
| Unknown | Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinica NCT05957939 | Ministry of Health, Saudi Arabia | Phase 1 |
| Active Not Recruiting | Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation NCT05491226 | Stephen Shiao | Phase 2 |
| Recruiting | CtDNA Based MRD Testing for NAC Monitoring in TNBC NCT06230185 | Personalis Inc. | — |
| Recruiting | The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negati NCT06125080 | Huihua Xiong | Phase 2 |
| Recruiting | Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251 | Avenzo Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in P NCT05999149 | Fudan University | Phase 3 |
| Unknown | An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE NCT05928780 | Fudan University | Phase 1 / Phase 2 |
| Recruiting | Study of LP-184 in Patients With Advanced Solid Tumors NCT05933265 | Lantern Pharma Inc. | Phase 1 / Phase 2 |
| Recruiting | A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Th NCT05862064 | Fudan University | Phase 3 |
| Recruiting | Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer NCT05834582 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) NCT05660083 | The Methodist Hospital Research Institute | Phase 2 |
| Recruiting | BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia NCT05768932 | SillaJen, Inc. | Phase 1 |
| Completed | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizum NCT05585034 | Xencor, Inc. | Phase 1 |
| Recruiting | Role of the Immune Environment in Response to Therapy in Breast Cancer NCT05396612 | Abramson Cancer Center at Penn Medicine | — |
| Unknown | To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Ea NCT05491694 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Active Not Recruiting | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer NCT05451849 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Recruiting | PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-n NCT06059469 | Jules Bordet Institute | Phase 2 |
| Terminated | A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451 | Lyell Immunopharma, Inc. | Phase 1 |
| Terminated | RTX-224 Monotherapy in Patients With Solid Tumors NCT05219578 | Rubius Therapeutics | Phase 1 / Phase 2 |
| Unknown | Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Ca NCT05402722 | Beijing 302 Hospital | Phase 2 |
| Recruiting | Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer NCT05541367 | Tongji Hospital | — |
| Withdrawn | Breast Cancer BRCA1 Carriers: a Pilot Study NCT05062174 | Indiana University | — |
| Active Not Recruiting | Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer NCT04674306 | George T. Budd | EARLY_Phase 1 |
| Completed | PhI to Solid Tumors and PhII to Locally Advanced or mTNBC NCT05390710 | Laekna Limited | Phase 1 |
| Completed | Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Nega NCT04799249 | G1 Therapeutics, Inc. | Phase 3 |
| Recruiting | A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Tripl NCT04683679 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | TH1902 in Patients With Advanced Solid Tumors NCT04706962 | Theratechnologies | Phase 1 |
| Unknown | Talazoparib Maintenance Therapy in Triple-negative Breast Cancer NCT04755868 | Yonsei University | Phase 2 |
| Unknown | An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. NCT04395989 | Fudan University | Phase 2 |
| Terminated | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patie NCT03199040 | Washington University School of Medicine | Phase 1 |
| Terminated | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors NCT03875313 | Calithera Biosciences, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers NCT03911973 | Kari Wisinski | Phase 1 / Phase 2 |
| Active Not Recruiting | Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Ca NCT03808662 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Bre NCT03719326 | Arcus Biosciences, Inc. | Phase 1 |
| Terminated | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma NCT03207867 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms NCT03219268 | MacroGenics | Phase 1 |
| Completed | Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With NCT03057600 | Calithera Biosciences, Inc | Phase 2 |
| Recruiting | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379 | QuantumLeap Healthcare Collaborative | Phase 2 |
| Available | An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Pa NCT07536815 | CytoDyn, Inc. | — |